Is biotech too founder-friendly? Is honesty overrated? And how do you tell a good beep from a bad one?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a chat with Atlas Venture’s Bruce Booth about how biotech’s recent boom has changed the dynamic between VCs and entrepreneurs. Then we talk about the latest controversy surrounding doctors who take payments from the drug industry and fail to disclose them. And STAT’s Eric Boodman joins us to discuss why Medtronic reached out to an avant-garde electronic musician in the name of making medical devices more effective. And finally there’s a lightning round, featuring a unicorn IPO, a would-be Martin Shkreli, and the likely end of the CRISPR patent dispute.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy